Abstract

IntroductionTotal parkinsonian motor symptom severity correlates with presynaptic striatal dopamine function in patients with Parkinson’s disease. There is a lack of studies that have investigated the associations between parkinsonian motor signs and striatal dopaminergic deficiency in patients with parkinsonism of an unknown origin. Identification of specific motor signs associated with the highest likelihood of striatal dopamine deficiency could aid the differential diagnostics of parkinsonian and tremor syndromes.MethodsIn this cross-sectional clinical and imaging study, detailed motor examinations were performed for 221 patients with parkinsonism or tremor of an unknown origin immediately before dopamine transporter (DAT) [I-123]FP-CIT SPECT imaging. Region-of-interest and voxel-based methods were used to investigate striatal DAT deficiency in relation to individual motor signs.ResultsUpper extremity rigidity and facial expression were the only motor signs that differentiated patients with normal and abnormal striatal DAT function. The presence of any upper extremity rigidity showed the highest likelihood of DAT deficiency (OR 4.79, 95% CI 1.56–14.75, P = 0.006) followed by reduced facial expression (OR 2.14, 95% CI 1.14–4.00, P = 0.018). In patients with DAT deficits, reduced facial expression was associated with DAT deficiency specifically in the caudate nucleus, and increased upper extremity rigidity was associated with DAT loss in the dorsal putamen (FWE-corrected P < 0.05).ConclusionsIncreased upper extremity muscle tone and hypomimia are independently associated with a higher likelihood of striatal hypodopaminergic imaging finding. This information can be used as a factor when the clinical need of auxiliary investigations, such as DAT SPECT, is considered for patients with parkinsonism.

Highlights

  • Total parkinsonian motor symptom severity correlates with presynaptic striatal dopamine function in patients with Parkinson’s disease

  • The uptake of putaminal presynaptic dopaminergic tracers in positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging is decreased by approximately 50% in patients with early to moderate Parkinson’s disease (PD), with practically no overlap when compared to healthy individuals [3]

  • The differentiation of patients with essential tremor (ET) from neurodegenerative parkinsonism with dopamine transporter (DAT) SPECT imaging has shown a high diagnostic accuracy [4]. [I-123]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4iodophenyl)nortropane ([I-123]FP-CIT) SPECT can be used to establish the early diagnosis of neurodegenerative parkinsonism, in the differential diagnosis between dementia with Lewy bodies (DLB) and other dementias such as Alzheimer’s disease (AD), as well as between neurodegenerative parkinsonism with presynaptic dopamine loss (PD, DLB, multiple system atrophy MSA, progressive supranuclear palsy PSP and corticobasal syndrome CBS) and secondary parkinsonism, e.g., neuroleptic-induced parkinsonism [5]

Read more

Summary

Introduction

Total parkinsonian motor symptom severity correlates with presynaptic striatal dopamine function in patients with Parkinson’s disease. There is a lack of studies that have investigated the associations between parkinsonian motor signs and striatal dopaminergic deficiency in patients with parkinsonism of an unknown origin. Identification of specific motor signs associated with the highest likelihood of striatal dopamine deficiency could aid the differential diagnostics of parkinsonian and tremor syndromes. Conclusions Increased upper extremity muscle tone and hypomimia are independently associated with a higher likelihood of striatal hypodopaminergic imaging finding This information can be used as a factor when the clinical need of auxiliary investigations, such as DAT SPECT, is considered for patients with parkinsonism. The differentiation of patients with essential tremor (ET) from neurodegenerative parkinsonism with dopamine transporter (DAT) SPECT imaging has shown a high diagnostic accuracy [4]. The clinical evaluation of parkinsonism patients remains the gold standard in most regions of the world

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.